부산대학교 도서관

Background & Aims Lactulose and rifaximin have already been shown to improve both cognitive functions and health related quality of life ( HRQOL) in MHE patients. We aimed to compare the efficacy of rifaximin with lactulose in reversal of MHE and improvement in HRQOL in cirrhotic patients with MHE. Method This prospective, randomized, open label, non-inferiority trial, was conducted at the Gastroenterology department of a tertiary care institute in Northern India. MHE was diagnosed if any two of the five neuro-psychometric ( NP) tests were positive. HRQOL was assessed using the sickness impact profile ( SIP) questionnaire (John Hopkins University, USA). Results Of 527 cirrhotics screened, 351 were found eligible and tested for MHE. A total of 112 (31.9%) patients were found to have MHE and then randomized into two groups group A (lactulose; 30-120 ml/day) and B (Tablet. rifaximin; 400 mg thrice a day). Based on the intention-to-treat population, the proportion of patients with MHE reversal at 3 months was 73.7% (42/57) in the rifaximin arm and 69.1% (38/55) in the lactulose arm [4.6% difference (90% CI −9.3% to 18.4%)]. However, non-inferiority of rifaximin over lactulose could not be established as the pre-specified non-inferiority margin (−5%) lies within the two-sided 90% confidence interval of the difference. HRQOL was significantly improved in both groups ( P = 0.20). However, the proportion of patients with flatulence ( P = 0.004) and diarrhoea ( P = 0.0002) was significantly higher in patients who took lactulose. Conclusion Non-inferiority of rifaximin over lactulose for MHE reversal was not established. [ABSTRACT FROM AUTHOR]